EcoDrugPlus

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSACLG00000017628
Gene Symbol: CACNA1BA
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSACLG00000010494
Gene Symbol: CACNA1AB
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSACLG00000000969
Gene Symbol: CACNB1
1 Cross references
210 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 2a

Ensembl ID : ENSACLG00000000867
Gene Symbol: CACNB2A
1 Cross references
204 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1a

Ensembl ID : ENSACLG00000002262
Gene Symbol: CACNG1A
1 Cross references
196 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSACLG00000018246
Gene Symbol: CASR
3 Cross references
203 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSACLG00000024948
Gene Symbol: CACNA2D1
1 Cross references
229 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSACLG00000014219
Gene Symbol: CACNA2D2
3 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSACLG00000018911
Gene Symbol: CACNA2D2
3 Cross references
200 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSACLG00000008943
Gene Symbol: CACNA2D3
2 Cross references
216 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSACLG00000002230
Gene Symbol: CACNA2D4
2 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSACLG00000026271
Gene Symbol: CACNA2D4
1 Cross references
234 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).